Payment overview · 2025
General Payments
$136.37
7 reported records · 5 companies
Healthcare provider profile · identity verified
Troy E Hutcheson, PA
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant|Medical · AUGUSTA, GA · NPI 1306057328
Verified facts
What the public records show
CMS Open Payments records show Troy E Hutcheson, PA received $136.37 in general payments during 2025 across 7 reported records.
Lilly USA, LLC accounted for 43.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Vraylar by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $59.19 | 43.4% | 3 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $25.31 | 18.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.88 | 13.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.04 | 13.2% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.95 | 11.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $136.37 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $40.41 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $37.97 | 2 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $25.31 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $18.88 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.04 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $14.95 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
45 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 474 | 152 |
| Atorvastatin Calcium | Atorvastatin Calcium | 468 | 154 |
| Losartan Potassium | Losartan Potassium | 373 | 119 |
| Gabapentin | Gabapentin | 289 | 90 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 285 | 98 |
| Hydrochlorothiazide | Hydrochlorothiazide | 274 | 84 |
| Metformin Hcl | Metformin Hcl | 230 | 69 |
| Pantoprazole Sodium | Pantoprazole Sodium | 220 | 69 |
| Levothyroxine Sodium | Levothyroxine Sodium | 194 | 51 |
| Furosemide | Furosemide | 189 | 65 |
| Lisinopril | Lisinopril | 189 | 63 |
| Diclofenac Sodium | Diclofenac Sodium | 175 | 55 |
| Carvedilol | Carvedilol | 153 | 45 |
| Meloxicam | Meloxicam | 153 | 50 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 150 | 64 |
| Ibuprofen | Ibuprofen | 150 | 52 |
| Omeprazole | Omeprazole | 138 | 44 |
| Hydralazine Hcl | Hydralazine Hcl | 133 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 131 | 45 |
| Simvastatin | Simvastatin | 119 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 119 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 115 | 37 |
| Glipizide | Glipizide | 112 | 30 |
| Eliquis | Apixaban | 105 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 105 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 100 | 32 |
| Azithromycin | Azithromycin | 99 | 73 |
| Sertraline Hcl | Sertraline Hcl | 96 | 32 |
| Allopurinol | Allopurinol | 90 | 25 |
| Methylprednisolone | Methylprednisolone | 89 | 71 |
| Potassium Chloride | Potassium Chloride | 88 | 31 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 87 | 66 |
| Trazodone Hcl | Trazodone Hcl | 86 | 30 |
| Baclofen | Baclofen | 85 | 25 |
| Ozempic | Semaglutide | 81 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 79 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 76 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 76 | 24 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 75 | 31 |
| Famotidine | Famotidine | 74 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 74 | 24 |
| Glimepiride | Glimepiride | 70 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 67 | 19 |
| Montelukast Sodium | Montelukast Sodium | 66 | 26 |
| Ventolin Hfa | Albuterol Sulfate | 66 | 22 |
| Atenolol | Atenolol | 61 | 21 |
| Tramadol Hcl | Tramadol Hcl | 61 | 17 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 60 | 15 |
| Ibu | Ibuprofen | 59 | 24 |
| Doxycycline Hyclate | Doxycycline Hyclate | 58 | 44 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 58 | 27 |
| Pregabalin | Pregabalin | 53 | 15 |
| Farxiga | Dapagliflozin Propanediol | 52 | 18 |
| Meclizine Hcl | Meclizine Hcl | 52 | 19 |
| Metformin Hcl Er | Metformin Hcl | 52 | 17 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 51 | 17 |
| Chlorthalidone | Chlorthalidone | 50 | 17 |
| Januvia | Sitagliptin Phosphate | 48 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 47 | 14 |
| Spironolactone | Spironolactone | 47 | 17 |
| Symbicort | Budesonide/Formoterol Fumarate | 47 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 45 | 14 |
| Jardiance | Empagliflozin | 45 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 40 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 40 | 12 |
| Alendronate Sodium | Alendronate Sodium | 39 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 39 | 11 |
| Fluconazole | Fluconazole | 39 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 39 | suppressed |
| Lovastatin | Lovastatin | 38 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 37 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 37 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 31 |
| Celecoxib | Celecoxib | 34 | 13 |
| Glipizide Er | Glipizide | 34 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Cephalexin | Cephalexin | 33 | 31 |
| Clonidine Hcl | Clonidine Hcl | 33 | 12 |
| Colchicine | Colchicine | 33 | 13 |
| Donepezil Hcl | Donepezil Hcl | 33 | 11 |
| Linzess | Linaclotide | 33 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 31 | suppressed |
| Mounjaro | Tirzepatide | 30 | suppressed |
| Myrbetriq | Mirabegron | 30 | suppressed |
| Nystatin | Nystatin | 30 | 11 |
| Prednisone | Prednisone | 30 | 21 |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Risperidone | Risperidone | 29 | suppressed |
| Acyclovir | Acyclovir | 28 | 11 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 28 | suppressed |
| Vraylar | Cariprazine Hcl | 28 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 28 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 27 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 27 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Naproxen | Naproxen | 26 | 13 |
| Metronidazole | Metronidazole | 25 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Tradjenta | Linagliptin | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 22 | suppressed |
| Bumetanide | Bumetanide | 21 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 21 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 15 |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | 11 |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | 11 |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Humira(Cf) Pen | Adalimumab | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Tobramycin | Tobramycin | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Alprazolam | Alprazolam | 11 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Ezetimibe | Ezetimibe | 11 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $136.37 · 7 records | Lilly USA, LLC | Cologuard Collection Kit, JOURNAVX, MOUNJARO, VERQUVO, VRAYLAR, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error